- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04638491
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Phase 1, Single-arm, Open-label, Dose Escalating and Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of Lurbinectedin (PM01183) for Injection in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: wu chunjiao, Doctor
- Phone Number: 18643112151
- Email: 2956519672@.com
Study Contact Backup
- Name: xing juying, bachelor
- Phone Number: 13039116978
Study Locations
-
-
Jilin
-
Changchun, Jilin, China
- Recruiting
- Jilin Provincial Tumor Hospital
-
Contact:
- chunjiao wu
- Phone Number: 18643112151
- Email: 2956519672@.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Voluntary written informed consent of the patient.
- 2. Age≥18 years.
- 3. Escalating stage: Patients with histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to standard therapy or for whom refuses or cannot tolerate standard treatment or no standard therapy exist (no more than three prior regimens for advanced or unresectable disease).
- 4. Expansion stage: Patients with histologically confirmed diagnosis of advanced or unresectable SCLC who had failure to one prior platinum -containing line.
- 5. Measurable disease as defined by the RECIST v.1.1.
- 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
- 7. Life expectancy ≥3 months.
- 8. Adequate bone marrow, renal, hepatic, and metabolic function as follows: Platelet count ≥ 100 x 109/l, Hemoglobin ≥ 90 g/l, absolute neutrophil count (ANC) ≥ 2.0 x 109/l; Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN), ≤ 5.0 x ULN if presence of liver metastases; Alkaline phosphatase ≤ 5.0 x ULN ; Total bilirubin ≤ 1.5 x ULN, and direct bilirubin ≤1 x ULN ; Serum creatinine ≤ 1.5 x ULN or Calculated creatinine clearance: ≥ 30 ml/min (calculated using the Cockcroft and Gault formula); Creatine phosphokinase (CPK) ≤ 2.5 x ULN; Albumin ≥ 3 g/dl.
- 9. Recovery to grade ≤ 1 according to the NCI-CTCAE v.5.0, of any ongoing adverse event derived from previous treatment ( with the exception of grade 2 alopecia and non-painful peripheral sensory neuropathy ).
- 10. Women of childbearing potential must have a negative serum pregnancy test before study entry. Women of childbearing potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 6 months after discontinuation of treatment. Male patients (female partners is of childbearing potential ) take effective contraceptive measures throughout the treatment period and for 4 months after discontinuation of treatment.
Exclusion Criteria:
- 1. Prior treatment with trabectedin.
- 2. Patients with brain metastases, a history of spinal cord compression, or meningeal metastases.
- 3. Suspected or confirmed disease bone marrow involved.
- 4. Bone metastases, obstructive atelectasis, superior vena cava syndrome patients with local symptoms that may require radiotherapy/surgery/endoscopic treatment/interventional intervention; patients with suspected or confirmed pulmonary embolism; uncontrollable large amounts of pleural fluid, ascites and pericardial effusion.
- 5. Patients who received other recent antitumor therapies ( with respect to study treatment start ) : Less than three weeks since the last chemotherapy-containing regimen (six weeks in case of nitrosoureas, mitomycin C ).
Less than four weeks since the last monoclonal antibody-containing therapy or radiotherapy (RT) dose >30 Gy.
Less than two weeks since the last any other biological/investigational anticancer therapy or palliative radiotherapy ( total dose ≤30 Gy).
- 6. Concomitant diseases/conditions: History (during the last year) or presence of any of the following: unstable angina, myocardial infarction, New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), or clinically significant valvular heart disease; History of stroke within 1 year (including ischemic stroke, hemorrhagic stroke); Patients with uncontrolled hypertension (systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 100 mmHg); History of hypertensive crisis or hypertensive encephalopathy; Severe arrhythmia requiring ongoing pharmacological treatment; Positive tests for Hepatitis B surface antigen (HBsAg) and the peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) titer test is ≥1×103 copies/mL; if the HBsAg is positive, and the peripheral blood HBV DNA titer test is <1×103 copies/ml and in the Investigator's judgment, the patient is under a stable stage of chronic hepatitis B and does not increase the risk of the patient, then the patient is eligible for selection; HCV antibody positive or HIV antibody positive; Active uncontrolled infection requiring ongoing medical treatment within two weeks prior to treatment start.
Evidence of bleeding diathesis or significant coagulopathy; Prior or concurrent invasive malignancy other than the primary study indication within 5 years prior to treatment start, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection; Any other major illness that, in the Investigator's judgment, not suitable for inclusion in this study.
- 7. History of previous bone marrow and/or stem cell transplantation.
- 8. Prior medication requirements: Patients who have used strong inducers or inhibitors of cytochrome P450 3A4 enzyme (CYP3A4) within 2 weeks or 5 half-lives ( whichever is longer ) prior to treatment start; Prophylaxis or treatment for non-febrile neutropenia with G-CSF within two weeks prior to treatment start; Patients who have used erythropoietin and derivatives within 3 weeks prior to treatment start; Patients who have used blood transfusions within 2 weeks prior to treatment start.
- 9. Patients who may need to receive other systemic anti-tumor or radical treatments for local target/non-target lesions during the study period;
- 10. Known history of psychotropic drug, alcohol or drug abuse;
- 11. Known to be allergic to any component of the investigational drug;
- 12. Pregnant or breastfeeding women, or women of childbearing potential have a positive blood pregnancy test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single-arm
PM01183-Dose Escalation
|
On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate(ORR)
Time Frame: From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
The number and percentage of subjects with significant remission (CR + PR) were calculated, and the 95% confidence interval of the percentage was calculat
|
From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate(DCR)
Time Frame: From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
The number and percentage of subjects with disease control (CR+PR+SD) were calculated, and the 95% confidence interval of the percentage was calculated
|
From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Progression Free Survival(PFS)
Time Frame: From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Survival analysis (Kaplan Meier method) was used to estimate the median dor and its 95% confidence interval (CI), and the K-M curve was drawn
|
From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Overall Survival(OS)
Time Frame: From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Survival analysis (Kaplan Meier method) was used to estimate the median dor and its 95% confidence interval (CI), and the K-M curve was drawn
|
From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Duration of remission (DOR)
Time Frame: From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Survival analysis (Kaplan Meier method) was used to estimate the median dor and its 95% confidence interval (CI), and the K-M curve was drawn
|
From date of first administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months(each cycle is 21 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: cheng ying, Doctor, Jilin Provincial Tumor Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LY01017/CT-CHN-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Lurbinectedin for injection
-
HonorHealth Research InstituteJazz PharmaceuticalsRecruitingGastrointestinal MalignanciesUnited States
-
Children's Hospital of PhiladelphiaJazz Pharmaceuticals; Stand Up To CancerRecruitingEwing Sarcoma | Pediatric Cancer | Desmoplastic Small Round Cell Tumor | Undifferentiated SarcomaUnited States
-
Intergroupe Francophone de Cancerologie ThoraciquePharmaMar; Groupe Francais De Pneumo-CancerologieCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedMalignant Pleural Mesothelioma, AdvancedSwitzerland, Italy
-
Jazz PharmaceuticalsRecruitingEwing Sarcoma | Refractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited States, Canada
-
UNC Lineberger Comprehensive Cancer CenterG1 Therapeutics, Inc.Recruiting
-
Jazz PharmaceuticalsRecruitingExtensive-stage Small-cell Lung CancerUnited States, Canada
-
National Cancer Institute (NCI)RecruitingSCLC | Advanced Solid Tumor | Small Cell Cancer | High Grade Neuroendocrine CancersUnited States
-
Emory UniversityNational Cancer Institute (NCI); Jazz PharmaceuticalsRecruitingStage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell CarcinomaUnited States
-
PharmaMarCompletedSolid TumorsSpain, United States